These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 36427777)

  • 41. The moderating role of absorptive capacity and the differential effects of acquisitions and alliances on Big Pharma firms' innovation performance.
    Fernald KD; Pennings HP; van den Bosch JF; Commandeur HR; Claassen E
    PLoS One; 2017; 12(2):e0172488. PubMed ID: 28231332
    [TBL] [Abstract][Full Text] [Related]  

  • 42. An apple a day - how the platform economy impacts value creation in the healthcare market.
    Gleiss A; Kohlhagen M; Pousttchi K
    Electron Mark; 2021; 31(4):849-876. PubMed ID: 35599688
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The Physician on a Board of Directors: Bane or Benefit?
    Borow M; Levi B; Avissar B; Wapner L
    J Healthc Leadersh; 2022; 14():17-23. PubMed ID: 35241943
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Partnerships in Pharma--An Economist Intelligence Unit Seminar--Building Innovation into Alliances and Business Models. 1 October 2010, London, UK.
    Kibble A
    IDrugs; 2010 Dec; 13(12):813-5. PubMed ID: 21154130
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [The Renaissance of Russian pharmaceutical market (2000-2004). Report II. The Pharma servants of Russia].
    Zatravkin SN; Vishlenkova EA; Ignatiev VG
    Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med; 2023 Jan; 31(1):112-119. PubMed ID: 36801885
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Big data augmentated business trend identification: the case of mobile commerce.
    Saritas O; Bakhtin P; Kuzminov I; Khabirova E
    Scientometrics; 2021; 126(2):1553-1579. PubMed ID: 33424052
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Excluding NICE from early stages of value based pricing scheme was "big win for pharma," conference is told.
    Limb M
    BMJ; 2013 Nov; 347():f6906. PubMed ID: 24246840
    [No Abstract]   [Full Text] [Related]  

  • 48. Planning your niche in the "high tech" home care market.
    Louden TL
    Caring; 1985 Jan; 4(1):21-5. PubMed ID: 10270579
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Financial Times Global Pharmaceutical & Biotechnology Conference 2009.
    Scattereggia J
    IDrugs; 2010 Jan; 13(1):26-9. PubMed ID: 20024844
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Powered by Open Innovation: Opportunities and Challenges in the Pharma Sector.
    Martinez-Grau MA; Alvim-Gaston M
    Pharmaceut Med; 2019 Jun; 33(3):193-198. PubMed ID: 31933287
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evaluating communication partner training in healthcare centres: Understanding the mechanisms of behaviour change.
    van Rijssen M; Ketelaar M; Vandenborre D; Oostveen J; Veldkamp M; van Ewijk L; Visser-Meily JMA; Gerrits E
    Int J Lang Commun Disord; 2021 Nov; 56(6):1190-1203. PubMed ID: 34370352
    [TBL] [Abstract][Full Text] [Related]  

  • 52. On markets and morals--(re-)establishing independent decision making in healthcare: a reply to Joao Calinas-Correia.
    Sahm S
    Med Health Care Philos; 2013 May; 16(2):311-5. PubMed ID: 22331476
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Exploring the Development of Chinese Digital Resources under Lightweight Deep Learning.
    Song B
    Comput Intell Neurosci; 2022; 2022():3759129. PubMed ID: 35814587
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Helping science and drug development to succeed through pharma-academia partnerships: Yale Healthcare Conference 2013.
    Yang DX; Kim YA
    Yale J Biol Med; 2013 Sep; 86(3):429-32. PubMed ID: 24058318
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Data-Driven Modeling of Complex Business Process in Heterogeneous Environment of Healthcare Organization with Health Information Systems.
    Kshenin A; Kovalchuk S
    Stud Health Technol Inform; 2021 Oct; 285():118-123. PubMed ID: 34734861
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Towards a Computational Approach for the Assessment of Compliance of ALCOA+ Principles in Pharma Industry.
    Durá M; Sánchez-García Á; Sáez C; Leal F; Chis AE; González-Vélez H; García-Gómez JM
    Stud Health Technol Inform; 2022 May; 294():755-759. PubMed ID: 35612198
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Research on the influence mechanism and governance mechanism of digital divide for the elderly on wisdom healthcare: The role of artificial intelligence and big data.
    Zhou J; Wang Z; Liu Y; Yang J
    Front Public Health; 2022; 10():837238. PubMed ID: 36062111
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Decision-Making based on Big Data Analytics for People Management in Healthcare Organizations.
    Sousa MJ; Pesqueira AM; Lemos C; Sousa M; Rocha Á
    J Med Syst; 2019 Jul; 43(9):290. PubMed ID: 31332535
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Awareness and Perceptions among Members of a Japanese Cancer Patient Advocacy Group Concerning the Financial Relationships between the Pharmaceutical Industry and Physicians.
    Murayama A; Senoo Y; Harada K; Kotera Y; Saito H; Sawano T; Suzuki Y; Tanimoto T; Ozaki A
    Int J Environ Res Public Health; 2022 Mar; 19(6):. PubMed ID: 35329160
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Parallel problems: Applying institutional corruption analysis of Congress to big pharma.
    Fields G
    J Law Med Ethics; 2013; 41(3):556-60. PubMed ID: 24088145
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.